Sectors

NICE questions value and efficacy of five Covid-19 drugs with rejection

This week, NICE rejected five major Covid-19 therapies due to high costs and uncertainties in clinical evidence.

Clinical Trials

View More

Drug Manufacturers

View More

Therapy Area

View More